Literature DB >> 19733916

NALT (nasal cavity-associated lymphoid tissue) in the rabbit.

C Casteleyn1, A M C Broos, P Simoens, W Van den Broeck.   

Abstract

Due to its many advantages, interest in intranasal vaccination of domestic mammals and humans is currently increasing. Successful stimulation of the immune system by intranasal vaccines requires, however, the presence of lymphoid tissue in the nasal cavity. This nasal cavity-associated lymphoid tissue (NALT) has already been described in humans and many laboratory rodents, but data about rabbits are very scarce. For this purpose, histological sections of the nasal cavities of 10 female adult New Zealand White rabbits were examined for the presence of lymphoid tissue. Primary (I) and secondary (II) lymphoid follicles divided by interfollicular regions were mainly present at the bottom of the ventral nasal meatus and the nasopharyngeal meatus from 1 to 3.3cm from the tip of the nose. In this region intraepithelial and lamina propria lymphocytes, and isolated lymphoid follicles (ILF's) were additionally seen at the dorsal and dorsolateral sides of the nasopharyngeal meatus and within the mucosae of the nasal conchae and the lateral nasal walls. Intraepithelial and lamina propria lymphocytes, and ILF's were, just like in humans, randomly distributed along the entire nasal mucosa. The rabbit NALT is more voluminous compared to rodents in which lymphoid tissue is only present at the bottom of the nasopharyngeal meatus. Since the relative volume of the rabbit nasal cavity is also similar to that of humans, the rabbit could be a valuable research model not only for animal but also for human intranasal vaccine development. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2009        PMID: 19733916     DOI: 10.1016/j.vetimm.2009.08.011

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  15 in total

1.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

Review 2.  The evolution of nasal immune systems in vertebrates.

Authors:  Ali Sepahi; Irene Salinas
Journal:  Mol Immunol       Date:  2015-09-19       Impact factor: 4.407

3.  Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue.

Authors:  Stefan Fernandez; Emily D Cisney; Shannan I Hall; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2011-02-16

4.  Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.

Authors:  Dorothy I Jones; Justin J Pollara; Brandi T Johnson-Weaver; Celia C LaBranche; David C Montefiori; David J Pickup; Sallie R Permar; Soman N Abraham; Massimo Maddaloni; David W Pascual; Herman F Staats
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

5.  On the design of particle filters inspired by animal noses.

Authors:  Jisoo Yuk; Aneek Chakraborty; Shyuan Cheng; Chun-I Chung; Ashley Jorgensen; Saikat Basu; Leonardo P Chamorro; Sunghwan Jung
Journal:  J R Soc Interface       Date:  2022-03-02       Impact factor: 4.118

6.  Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery.

Authors:  Stefan Fernandez; Emily D Cisney; Robert G Ulrich
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

7.  Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge.

Authors:  Dorothy I Jones; Charles E McGee; Christopher J Sample; Gregory D Sempowski; David J Pickup; Herman F Staats
Journal:  Clin Vaccine Immunol       Date:  2016-07-05

8.  Characterization of New Zealand White Rabbit Gut-Associated Lymphoid Tissues and Use as Viral Oncology Animal Model.

Authors:  Robyn A Haines; Rebeccah A Urbiztondo; Rashade A H Haynes; Elaine Simpson; Stefan Niewiesk; Michael D Lairmore
Journal:  ILAR J       Date:  2016

9.  Examining the role of nasopharyngeal-associated lymphoreticular tissue (NALT) in mouse responses to vaccines.

Authors:  Emily D Cisney; Stefan Fernandez; Shannan I Hall; Gale A Krietz; Robert G Ulrich
Journal:  J Vis Exp       Date:  2012-08-01       Impact factor: 1.355

10.  Mucosal targeting of a BoNT/A subunit vaccine adjuvanted with a mast cell activator enhances induction of BoNT/A neutralizing antibodies in rabbits.

Authors:  Herman F Staats; Jeffrey R Fielhauer; Afton L Thompson; Alice A Tripp; Ashley E Sobel; Massimo Maddaloni; Soman N Abraham; David W Pascual
Journal:  PLoS One       Date:  2011-01-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.